BRPI0713378A8 - composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto - Google Patents
composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um compostoInfo
- Publication number
- BRPI0713378A8 BRPI0713378A8 BRPI0713378A BRPI0713378A BRPI0713378A8 BR PI0713378 A8 BRPI0713378 A8 BR PI0713378A8 BR PI0713378 A BRPI0713378 A BR PI0713378A BR PI0713378 A BRPI0713378 A BR PI0713378A BR PI0713378 A8 BRPI0713378 A8 BR PI0713378A8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- prodrug
- receptor function
- producing
- optically active
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
Abstract
composto, pró-droga, modulador da função do receptor gpr4o, agente farmacêutico, uso do composto, e, método de produção de uma forma opticamente ativa de um composto. a presente invenção fornece um composto representado pela fórmula (i): em que cada símbolo é como definido na descrição ou um sal do mesmo. o composto ou um sal do mesmo, ou uma pró-droga do mesmo, tem uma ação moduladora da função do receptor gpr4o e é útil como um secretagogo de insulina ou um agente para a profilaxia ou tratamento de diabetes e similares.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006177099 | 2006-06-27 | ||
JP2006-177099 | 2006-06-27 | ||
PCT/JP2007/063208 WO2008001931A2 (en) | 2006-06-27 | 2007-06-26 | Fused cyclic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0713378A2 BRPI0713378A2 (pt) | 2012-04-03 |
BRPI0713378A8 true BRPI0713378A8 (pt) | 2018-01-02 |
Family
ID=38656568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0713378A BRPI0713378A8 (pt) | 2006-06-27 | 2007-06-26 | composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto |
Country Status (37)
Country | Link |
---|---|
US (5) | US7732626B2 (pt) |
EP (4) | EP2743268A3 (pt) |
JP (3) | JP4401428B2 (pt) |
KR (1) | KR101058772B1 (pt) |
CN (4) | CN101616913B (pt) |
AR (1) | AR061644A1 (pt) |
AT (1) | ATE543815T1 (pt) |
AU (1) | AU2007265966B2 (pt) |
BR (1) | BRPI0713378A8 (pt) |
CA (2) | CA2656003C (pt) |
CL (1) | CL2007001873A1 (pt) |
CO (1) | CO6160234A2 (pt) |
CR (1) | CR10564A (pt) |
CY (2) | CY1112705T1 (pt) |
DK (2) | DK2041123T3 (pt) |
ES (2) | ES2379661T3 (pt) |
GE (1) | GEP20115359B (pt) |
HK (1) | HK1131126A1 (pt) |
HR (2) | HRP20120333T1 (pt) |
IL (1) | IL195947A (pt) |
JO (1) | JO2969B1 (pt) |
MA (1) | MA30537B1 (pt) |
ME (1) | ME00535B (pt) |
MX (1) | MX2008016274A (pt) |
MY (1) | MY154798A (pt) |
NO (1) | NO20090235L (pt) |
NZ (1) | NZ574038A (pt) |
PE (1) | PE20080993A1 (pt) |
PL (2) | PL2248812T3 (pt) |
PT (2) | PT2041123E (pt) |
RS (2) | RS53230B (pt) |
RU (1) | RU2444521C2 (pt) |
SI (2) | SI2041123T1 (pt) |
TW (1) | TWI354668B (pt) |
UA (1) | UA95296C2 (pt) |
WO (1) | WO2008001931A2 (pt) |
ZA (1) | ZA200900154B (pt) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
BRPI0818253A2 (pt) | 2007-10-10 | 2015-04-07 | Amgen Inc | Moduladores de gpr40 bifenil substituídos |
JP2011515341A (ja) * | 2008-03-06 | 2011-05-19 | アムジエン・インコーポレーテツド | 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体 |
WO2009117421A2 (en) * | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
CN102137836B (zh) | 2008-07-28 | 2015-08-26 | 赛丹思科大学 | 用于治疗代谢疾病的化合物 |
UY32126A (es) | 2008-09-25 | 2010-04-30 | Takeda Pharmaceutical | Composición farmacéutica sólida |
US8748462B2 (en) | 2008-10-15 | 2014-06-10 | Amgen Inc. | Spirocyclic GPR40 modulators |
EP2351743A4 (en) | 2008-10-27 | 2012-05-09 | Takeda Pharmaceutical | BICYCLIC CONNECTION |
AR074760A1 (es) * | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
EP2371826A4 (en) | 2008-12-29 | 2012-06-27 | Takeda Pharmaceutical | NEW CONNECTION WITH CONDENSED RINGS AND ITS USE |
US20100190747A1 (en) | 2009-01-27 | 2010-07-29 | Hideo Suzuki | Fused ring compound and use thereof |
JPWO2010123016A1 (ja) | 2009-04-22 | 2012-10-25 | アステラス製薬株式会社 | カルボン酸化合物 |
JP5657578B2 (ja) | 2009-06-09 | 2015-01-21 | 武田薬品工業株式会社 | 新規な縮合環化合物およびその用途 |
US20120129878A1 (en) | 2009-07-28 | 2012-05-24 | Takeda Pharmaceutical Company Limited | Tablet |
EP2495238A4 (en) | 2009-10-30 | 2013-04-24 | Mochida Pharm Co Ltd | NEW 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE |
EP2518060A4 (en) | 2009-12-25 | 2014-01-08 | Mochida Pharm Co Ltd | NEW 3-HYDROXY-5-ARYLISOTHIAZOL DERIVATIVE |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
NZ603777A (en) | 2010-04-27 | 2013-08-30 | Takeda Pharmaceutical | Bicyclic compound derivatives and their use as acc inhibitors. |
US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
EA022094B1 (ru) | 2010-06-16 | 2015-10-30 | Такеда Фармасьютикал Компани Лимитед | Кристаллическая форма амидного соединения |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
JP5816626B2 (ja) | 2010-09-17 | 2015-11-18 | 武田薬品工業株式会社 | 糖尿病治療剤 |
JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
AR084032A1 (es) | 2010-11-30 | 2013-04-17 | Takeda Pharmaceutical | Compuesto biciclico |
DK2646425T3 (en) | 2010-12-01 | 2015-08-24 | Boehringer Ingelheim Int | Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome. |
EP2675774A1 (en) * | 2011-02-17 | 2013-12-25 | Takeda Pharmaceutical Company Limited | Production method of optically active dihydrobenzofuran derivative |
JP6054368B2 (ja) | 2011-04-08 | 2016-12-27 | カルダン セラピューティクス リミテッドCaldan Therapeutics Limited | 代謝性疾患治療用o−フルオロ置換化合物またはその塩 |
AR085990A1 (es) | 2011-04-27 | 2013-11-13 | Mochida Pharm Co Ltd | Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen |
AU2012248627A1 (en) | 2011-04-28 | 2013-11-14 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN103012343B (zh) * | 2011-09-26 | 2015-04-08 | 上海恒瑞医药有限公司 | 稠合环类衍生物、其制备方法及其在医药上的应用 |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2772485A4 (en) | 2011-10-24 | 2015-06-10 | Takeda Pharmaceutical | BICYCLIC CONNECTION |
JP6122871B2 (ja) * | 2012-01-12 | 2017-04-26 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | 多環式化合物誘導体、それらの製造方法および医薬用途 |
US9365540B2 (en) | 2012-01-12 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as MCH receptor antagonists |
GB2498968A (en) * | 2012-02-01 | 2013-08-07 | Prosidion Ltd | Pharmaceutical combination of a GPR119 agonist and a GPR40 agonist |
US9181186B2 (en) | 2012-02-13 | 2015-11-10 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
JP6095580B2 (ja) | 2012-02-13 | 2017-03-15 | 武田薬品工業株式会社 | 芳香環化合物 |
JP6077555B2 (ja) | 2012-02-15 | 2017-02-08 | 武田薬品工業株式会社 | 錠剤 |
EP2838891B1 (en) | 2012-02-24 | 2017-08-02 | Takeda Pharmaceutical Company Limited | Aromatic ring compound as ghrelin o-acyltransferase inhibitor |
NZ631569A (en) | 2012-02-28 | 2016-10-28 | Piramal Entpr Ltd | Phenyl alkanoic acid derivatives as gpr agonists |
US8642585B2 (en) * | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
JPWO2013147026A1 (ja) | 2012-03-29 | 2015-12-14 | 武田薬品工業株式会社 | 芳香環化合物 |
US8809376B2 (en) | 2012-04-30 | 2014-08-19 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
WO2013168760A1 (ja) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | 芳香環化合物 |
EP2848621A4 (en) | 2012-05-10 | 2016-06-01 | Takeda Pharmaceutical | AROMATIC CYCLIC COMPOUND |
KR102145641B1 (ko) | 2012-06-05 | 2020-08-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 고형 제제 |
AR091739A1 (es) | 2012-07-11 | 2015-02-25 | Elcelyx Therapeutics Inc | Composiciones y metodos para reducir el riesgo cardiometabolico |
JP2015127299A (ja) | 2012-07-19 | 2015-07-09 | 武田薬品工業株式会社 | 固形製剤 |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP6262733B2 (ja) | 2012-09-04 | 2018-01-17 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドShanghai Hengrui Pharmaceutical Co., Ltd. | イミダゾリン誘導体、その製造法、およびそれらの医薬への適用 |
WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
TWI692469B (zh) * | 2012-11-09 | 2020-05-01 | 南韓商Lg化學股份有限公司 | Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
MX358499B (es) | 2012-11-16 | 2018-08-23 | Bristol Myers Squibb Co | Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40). |
EA201500574A1 (ru) | 2012-11-28 | 2015-11-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые инданилоксидигидробензофуранилуксусные кислоты |
US20140163025A1 (en) | 2012-12-07 | 2014-06-12 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
WO2014122067A1 (en) | 2013-02-06 | 2014-08-14 | Boehringer Ingelheim International Gmbh | New indanyloxydihydrobenzofuranylacetic acids |
BR112015019836A2 (pt) | 2013-02-22 | 2017-07-18 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto |
AU2014221489B2 (en) * | 2013-02-28 | 2018-03-08 | Tiumbio Co., Ltd. | Tricyclic compound and use thereof |
CN103145663B (zh) * | 2013-03-01 | 2016-03-23 | 上海高准医药有限公司 | (s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物,其制备方法及其在医药上的应用 |
WO2014142363A1 (en) | 2013-03-14 | 2014-09-18 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists |
CN104059039B (zh) * | 2013-03-22 | 2017-03-15 | 正大天晴药业集团股份有限公司 | 具有gpr40受体功能调节作用的稠环化合物 |
WO2014165816A1 (en) | 2013-04-05 | 2014-10-09 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
WO2014170842A2 (en) | 2013-04-17 | 2014-10-23 | Piramal Enterprises Limited | Substituted alkyl carboxylic acid derivatives as gpr agonists |
CN104870429B (zh) * | 2013-05-22 | 2017-05-03 | 四川海思科制药有限公司 | 苯并呋喃衍生物、其制备方法及其在医药上的应用 |
CN104250238B (zh) * | 2013-06-25 | 2017-12-26 | 南京圣和药业股份有限公司 | Gpr40激动剂及其应用 |
CN104250239B (zh) * | 2013-06-29 | 2016-09-07 | 山东轩竹医药科技有限公司 | 芳香多环羧酸衍生物 |
CN104507921B (zh) * | 2013-07-02 | 2017-02-22 | 四川海思科制药有限公司 | 苯并环丁烯类衍生物、其制备方法及其在医药上的应用 |
TW201536767A (zh) | 2013-07-09 | 2015-10-01 | Takeda Pharmaceutical | 雜環化合物 |
ES2672992T3 (es) | 2013-08-09 | 2018-06-19 | Takeda Pharmaceutical Company Limited | Compuesto aromático |
CN104370864B (zh) * | 2013-08-14 | 2016-04-13 | 成都苑东生物制药股份有限公司 | 一种2-(6-羟基-2,3-二氢苯并呋喃-3-基)乙腈化合物和以该化合物制备tak-875药物的方法 |
WO2015032328A1 (zh) * | 2013-09-03 | 2015-03-12 | 四川海思科制药有限公司 | 茚满衍生物及其制备方法和在医药上的应用 |
JO3442B1 (ar) | 2013-10-07 | 2019-10-20 | Takeda Pharmaceuticals Co | مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN104592211B (zh) * | 2013-10-31 | 2018-10-16 | 广东东阳光药业有限公司 | 联苯类化合物及其用途 |
CN105722841A (zh) | 2013-11-14 | 2016-06-29 | 卡迪拉保健有限公司 | 新型杂环化合物 |
ES2747973T3 (es) | 2013-11-15 | 2020-03-12 | Merck Sharp & Dohme | Compuestos tricíclicos antidiabéticos |
CN104650055A (zh) * | 2013-11-22 | 2015-05-27 | 山东轩竹医药科技有限公司 | 芳香多环羧酸衍生物 |
US9957219B2 (en) | 2013-12-04 | 2018-05-01 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
EP3102198B1 (en) | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
CN105001212B (zh) * | 2014-04-16 | 2018-01-16 | 江苏柯菲平医药股份有限公司 | 稠环化合物及其制备方法和应用 |
WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10968193B2 (en) | 2014-08-08 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
CN104177320B (zh) * | 2014-08-27 | 2016-03-02 | 广东东阳光药业有限公司 | 一种脲取代联苯类化合物及其组合物及用途 |
CN104193731B (zh) * | 2014-08-27 | 2017-03-15 | 广东东阳光药业有限公司 | 一种脲取代联苯类化合物及其组合物及用途 |
CN111423408A (zh) | 2014-10-17 | 2020-07-17 | 现代药品株式会社 | 代谢性疾病的预防或治疗用复合制剂 |
US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
CN105418563B (zh) * | 2015-12-28 | 2017-11-10 | 山东大学 | Tak‑875类似物及其制备方法与应用 |
WO2017172505A1 (en) | 2016-03-29 | 2017-10-05 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
EP3573952B1 (en) | 2017-01-26 | 2021-07-14 | Boehringer Ingelheim International GmbH | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof |
CN110198928B (zh) | 2017-01-26 | 2023-08-29 | 勃林格殷格翰国际有限公司 | 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途 |
JP7050792B2 (ja) | 2017-01-26 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
CN110248929B (zh) | 2017-01-26 | 2023-05-12 | 勃林格殷格翰国际有限公司 | 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途 |
US10550127B1 (en) | 2017-02-08 | 2020-02-04 | Boehringer Ingelheim International Gmbh | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes |
JOP20180029A1 (ar) | 2017-03-30 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب حلقي غير متجانس |
AR111199A1 (es) | 2017-03-31 | 2019-06-12 | Takeda Pharmaceuticals Co | Compuesto aromático agonista de gpr40 |
CA3058578A1 (en) | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Aromatic compound |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
WO2019099315A1 (en) | 2017-11-16 | 2019-05-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US11964938B2 (en) | 2018-01-08 | 2024-04-23 | Celon Pharma S.A. | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists |
TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
CN110294744A (zh) * | 2018-03-21 | 2019-10-01 | 中国医学科学院药物研究所 | Gpr40受体激动剂、其制法和其药物组合物与用途 |
AU2019237507A1 (en) | 2018-03-23 | 2020-10-08 | Carmot Therapeutics, Inc. | Modulators of G-protein coupled receptors |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
EP4234030A3 (en) | 2018-07-13 | 2023-10-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
JP6773938B2 (ja) | 2018-08-27 | 2020-10-21 | 株式会社スコヒアファーマ | 安息香酸エステル化合物 |
US20220016215A1 (en) | 2018-09-24 | 2022-01-20 | Takeda Phaarmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
JP2022503793A (ja) | 2018-09-24 | 2022-01-12 | 武田薬品工業株式会社 | Gip受容体アゴニストペプチド化合物及びその使用 |
CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
CN113677369A (zh) * | 2019-02-13 | 2021-11-19 | 嘉惟思远制药有限公司 | 用于预防或治疗骨疾病的药物组合物 |
WO2022034664A1 (ja) | 2020-08-12 | 2022-02-17 | 株式会社ジェクスヴァル | 骨疾患の予防または治療用の医薬組成物 |
MX2022011729A (es) | 2020-03-25 | 2022-10-13 | Takeda Pharmaceuticals Co | Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos. |
IL296592A (en) | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | One-day doses of gip receptor agonistic peptides and their uses |
WO2022133111A1 (en) * | 2020-12-16 | 2022-06-23 | Regents Of The University Of Minnesota | Cubanyl biguanide compounds |
TW202313666A (zh) | 2021-05-13 | 2023-04-01 | 美商卡默療法股份有限公司 | G-蛋白偶聯受體之調節劑 |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9309324D0 (en) | 1993-05-06 | 1993-06-16 | Bayer Ag | Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives |
US5489586A (en) | 1994-03-07 | 1996-02-06 | Warner-Lambert Company | Method for treating inflammatory disease in humans |
US5612330A (en) | 1994-03-07 | 1997-03-18 | Warner-Lambert Company | Methods for inhibiting and controlling viral growth |
CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
US5807876A (en) * | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
RU6023U1 (ru) | 1997-01-20 | 1998-02-16 | АО "Автоэлектроника" | Устройство управления для экономайзера принудительного холостого хода |
US6025372A (en) | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
AU1285499A (en) | 1997-10-30 | 1999-05-24 | Merck & Co., Inc. | Somatostatin agonists |
KR100693771B1 (ko) | 1999-04-28 | 2007-03-12 | 사노피-아벤티스 도이칠란트 게엠베하 | Ppar 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물 |
RU11297U1 (ru) | 1999-06-16 | 1999-09-16 | Курзанов Евгений Владимирович | Установка для выборочного измерения производительности нефтяных источников при групповом учете |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
WO2001014358A2 (en) | 1999-08-26 | 2001-03-01 | Aventis Pharmaceuticals Inc. | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans |
CA2386517A1 (en) | 1999-10-07 | 2001-04-12 | Takeda Chemical Industries, Ltd. | Amine derivatives |
BR0015466A (pt) | 1999-11-10 | 2002-08-06 | Takeda Chemical Industries Ltd | Composto, prodroga, composição farmacêutica, agentes para evitar ou tratar diabetes mellitus, hiperlipidemia e toler ncia à glicose prejudicada, para regular a função do receptor relacionado a retinóide e para melhorar a resistência à insulina e uso de um composto |
DE60018216T2 (de) * | 1999-12-24 | 2006-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Kondensierte purinderivate |
CA2407149C (en) | 2000-04-28 | 2010-10-12 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
AU2001256733A1 (en) | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
US6429223B1 (en) * | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
RU2340611C2 (ru) | 2000-09-15 | 2008-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразола, используемые в качестве ингибиторов протеинкиназы |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
DE60120193T2 (de) | 2000-09-15 | 2007-03-29 | Vertex Pharmaceuticals Inc., Cambridge | Pyrazolverbindungen als protein-kinasehemmer |
US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2001297625A1 (en) | 2000-12-21 | 2002-09-12 | Bristol-Myers Squibb Company | Nucleic acid molecules and polypeptides for a human cation channel polypeptide |
ATE528303T1 (de) | 2000-12-21 | 2011-10-15 | Vertex Pharma | Pyrazoleverbindungen als proteinkinasehemmer |
ES2231681T3 (es) | 2001-03-30 | 2005-05-16 | Pfizer Products Inc. | Inhibidores de piridazinona de la aldosa reductasa. |
TWI311133B (en) * | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
TW522326B (en) * | 2001-08-03 | 2003-03-01 | Inventec Corp | Real-time data customer service system and method thereof |
US6701066B2 (en) * | 2001-10-11 | 2004-03-02 | Micron Technology, Inc. | Delivery of solid chemical precursors |
EP1437351A4 (en) | 2001-10-19 | 2005-06-01 | Takeda Pharmaceutical | AMINE DERIVATIVE |
JP4166024B2 (ja) | 2002-03-07 | 2008-10-15 | 独立行政法人科学技術振興機構 | 2環式化合物およびその製造方法 |
ES2276097T3 (es) | 2002-04-26 | 2007-06-16 | F. Hoffmann-La Roche Ag | Fenilacetamidas sustituidas y su empleo0 como activadores de glucoquinasa. |
WO2004011469A1 (ja) * | 2002-07-26 | 2004-02-05 | Kyowa Hakko Kogyo Co., Ltd. | 細胞分化誘導剤 |
EP2385032A1 (en) | 2002-11-08 | 2011-11-09 | Takeda Pharmaceutical Company Limited | GPR40 Receptor function regulator |
US7572910B2 (en) | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
WO2004080943A1 (ja) * | 2003-03-11 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤 |
US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
CA2527691C (en) | 2003-05-30 | 2013-01-22 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
TW200523252A (en) | 2003-10-31 | 2005-07-16 | Takeda Pharmaceutical | Pyridine compounds |
RU2353617C2 (ru) | 2003-10-31 | 2009-04-27 | Такеда Фармасьютикал Компани Лимитед | Производные пиридина в качестве ингибиторов дипептидилпептидазы iv |
WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
JP4074616B2 (ja) * | 2003-12-25 | 2008-04-09 | 武田薬品工業株式会社 | 3−(4−ベンジルオキシフェニル)プロパン酸誘導体 |
TW200523247A (en) * | 2003-12-25 | 2005-07-16 | Takeda Pharmaceutical | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
US7585880B2 (en) * | 2003-12-26 | 2009-09-08 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
EP1726580A4 (en) * | 2004-03-15 | 2008-02-13 | Takeda Pharmaceutical | AMINOPHNYLPROPANO ACID DERIVATIVE |
WO2005095338A1 (ja) * | 2004-03-30 | 2005-10-13 | Takeda Pharmaceutical Company Limited | アルコキシフェニルプロパン酸誘導体 |
UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
TW200609219A (en) * | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
JP3689711B1 (ja) | 2004-12-24 | 2005-08-31 | 極東鋼弦コンクリート振興株式会社 | 真空グラウト注入方法 |
TW200637839A (en) | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
RU2007135339A (ru) | 2005-02-25 | 2009-03-27 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные пиридилуксусной кислоты |
TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
TW200811170A (en) * | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Urea derivatives of tropane, their preparation and their therapeutic application |
TW200811158A (en) * | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application |
-
2007
- 2007-06-26 RU RU2009102515/04A patent/RU2444521C2/ru active
- 2007-06-26 PT PT07767983T patent/PT2041123E/pt unknown
- 2007-06-26 CA CA2656003A patent/CA2656003C/en active Active
- 2007-06-26 DK DK07767983.5T patent/DK2041123T3/da active
- 2007-06-26 RS RS20140115A patent/RS53230B/en unknown
- 2007-06-26 GE GEAP200711077A patent/GEP20115359B/en unknown
- 2007-06-26 ME MEP-2008-901A patent/ME00535B/me unknown
- 2007-06-26 ES ES07767983T patent/ES2379661T3/es active Active
- 2007-06-26 TW TW096122999A patent/TWI354668B/zh not_active IP Right Cessation
- 2007-06-26 AT AT07767983T patent/ATE543815T1/de active
- 2007-06-26 EP EP13190005.2A patent/EP2743268A3/en not_active Withdrawn
- 2007-06-26 WO PCT/JP2007/063208 patent/WO2008001931A2/en active Application Filing
- 2007-06-26 EP EP10172951.5A patent/EP2248812B1/en active Active
- 2007-06-26 MY MYPI20085345A patent/MY154798A/en unknown
- 2007-06-26 KR KR1020097001696A patent/KR101058772B1/ko not_active IP Right Cessation
- 2007-06-26 BR BRPI0713378A patent/BRPI0713378A8/pt not_active IP Right Cessation
- 2007-06-26 RS RS20120169A patent/RS52307B/en unknown
- 2007-06-26 CN CN2007800320224A patent/CN101616913B/zh active Active
- 2007-06-26 PT PT101729515T patent/PT2248812E/pt unknown
- 2007-06-26 UA UAA200900604A patent/UA95296C2/uk unknown
- 2007-06-26 CN CN201210241482.0A patent/CN102731451B/zh active Active
- 2007-06-26 EP EP11194016A patent/EP2431367A3/en not_active Withdrawn
- 2007-06-26 PL PL10172951T patent/PL2248812T3/pl unknown
- 2007-06-26 NZ NZ574038A patent/NZ574038A/en not_active IP Right Cessation
- 2007-06-26 CN CN2012105303764A patent/CN103083307A/zh active Pending
- 2007-06-26 PE PE2007000827A patent/PE20080993A1/es not_active Application Discontinuation
- 2007-06-26 AU AU2007265966A patent/AU2007265966B2/en not_active Ceased
- 2007-06-26 ZA ZA200900154A patent/ZA200900154B/xx unknown
- 2007-06-26 CN CN2012105303389A patent/CN103070854A/zh active Pending
- 2007-06-26 PL PL07767983T patent/PL2041123T3/pl unknown
- 2007-06-26 CA CA2838448A patent/CA2838448A1/en not_active Abandoned
- 2007-06-26 JO JO2007260A patent/JO2969B1/en active
- 2007-06-26 DK DK10172951.5T patent/DK2248812T5/da active
- 2007-06-26 AR ARP070102823A patent/AR061644A1/es unknown
- 2007-06-26 US US12/308,699 patent/US7732626B2/en active Active
- 2007-06-26 EP EP07767983A patent/EP2041123B9/en active Active
- 2007-06-26 SI SI200730892T patent/SI2041123T1/sl unknown
- 2007-06-26 JP JP2008554357A patent/JP4401428B2/ja not_active Expired - Fee Related
- 2007-06-26 CL CL2007001873A patent/CL2007001873A1/es unknown
- 2007-06-26 SI SI200731426T patent/SI2248812T1/sl unknown
- 2007-06-26 MX MX2008016274A patent/MX2008016274A/es active IP Right Grant
- 2007-06-26 ES ES10172951.5T patent/ES2450081T3/es active Active
-
2008
- 2008-12-15 IL IL195947A patent/IL195947A/en not_active IP Right Cessation
- 2008-12-30 MA MA31524A patent/MA30537B1/fr unknown
-
2009
- 2009-01-14 NO NO20090235A patent/NO20090235L/no unknown
- 2009-01-16 CR CR10564A patent/CR10564A/es not_active IP Right Cessation
- 2009-01-26 CO CO09006709A patent/CO6160234A2/es unknown
- 2009-07-16 JP JP2009168271A patent/JP4917634B2/ja not_active Expired - Fee Related
- 2009-09-30 HK HK09109075.0A patent/HK1131126A1/xx not_active IP Right Cessation
-
2010
- 2010-03-17 US US12/659,695 patent/US8088821B2/en not_active Expired - Fee Related
-
2011
- 2011-11-02 US US13/287,639 patent/US8492430B2/en not_active Expired - Fee Related
- 2011-12-08 JP JP2011269300A patent/JP5409757B2/ja not_active Expired - Fee Related
-
2012
- 2012-04-16 HR HRP20120333TT patent/HRP20120333T1/hr unknown
- 2012-04-25 CY CY20121100396T patent/CY1112705T1/el unknown
-
2013
- 2013-06-05 US US13/910,374 patent/US8598226B2/en not_active Expired - Fee Related
- 2013-10-25 US US14/063,100 patent/US20140080891A1/en not_active Abandoned
-
2014
- 2014-03-05 HR HRP20140201TT patent/HRP20140201T1/hr unknown
- 2014-03-18 CY CY20141100213T patent/CY1114978T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0713378A8 (pt) | composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto | |
ECSP099330A (es) | Compuesto de indol | |
BRPI0913291A2 (pt) | composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto | |
BRPI0814299B8 (pt) | preparação sólida compreendendo alogliptina e cloridreto de metformina, uso de uma preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida | |
BR112013002250A2 (pt) | composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto. | |
BRPI0514316A (pt) | métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p) | |
CL2012002422A1 (es) | Método para tratar artritis por lupus activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral. | |
BR112013029271A2 (pt) | cicatrização de tecido | |
BR112012020311A2 (pt) | "compostos, medicamento, método para inibir um ciclo de divisão celular, método para a profilaxia ou tratamento de câncer, e, uso do composto." | |
BR112014025711A2 (pt) | composto, medicamento, e, uso de um composto | |
BR112013019932A2 (pt) | dispositivo de liberação de medicamento | |
CL2013000716A1 (es) | Un profarmaco o una sal del mismo que comprende un conjugado de exendina-conector; procedimiento de preparacion de dicho profarmaco; compuestos intermediarios; composicion farmaceutica que lo comprende, util para mejorar el control glucemico en pacientes con diabetes de tipo 2. | |
BRPI0711646C1 (pt) | solução aquosa estéril de um sal de ácido succínico | |
CL2012002423A1 (es) | Método para tratar lupus nefritis activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral; composición farmacéutica que comprende laquinimod y micofenolato mofetil. | |
BR112014031372A2 (pt) | implantes/procedimentos relacionados ao avanço da tuberosidade tibial | |
BRPI0508051A (pt) | derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes | |
AR065392A1 (es) | Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio | |
UY32131A (es) | Compuestos de anillo fusionado y uso de los mismos | |
BR112013033457A2 (pt) | dispositivo de processamento de meio | |
BRPI1008858A8 (pt) | Método para combate de xanthomonas em plantas úteis | |
CL2011001026A1 (es) | Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato. | |
BR112014014046A2 (pt) | composto, composição, e, método para tratar hiv | |
BRPI0916282B8 (pt) | uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica | |
BR112015026840A2 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto, e, método prevenir ou tratar hiperfosfatemia | |
BR112014011481A2 (pt) | hidrolisado de colágeno e seu uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2520 DE 25-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |